Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -53K | -48K | -58K | -3K | -3K |
| Operating Income | -311K | -367K | -2M | -2M | -8M |
| EBITDA | -311K | -367K | -2M | -2M | -8M |
| Net Income | -364K | -415K | -2M | -2M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.00562
+8.08% today
1Y Change
-36.14%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ProtoKinetix, Incorporated (PKTX) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 36.1% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +90.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +90.0%, free cash flow +48.7% with operating margin -746.7% and ROIC -145.2%. Valuation already assumes a fairly strong business story at price/sales 43.4. Stock Foundry combines PKTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PKTX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PKTX Max Drawdown
-55.56%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PKTX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$7.6M
-228.2% YoY
Free Cash Flow
-$951.5K
+3.0% YoY
Revenue Growth
+0.0%
EPS Growth
+90.0%
Gross Margin
-28.4%
Net Margin
-772.8%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -53K | -48K | -58K | -3K | -3K |
| Operating Income | -311K | -367K | -2M | -2M | -8M |
| EBITDA | -311K | -367K | -2M | -2M | -8M |
| Net Income | -364K | -415K | -2M | -2M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | -5K | 20K | 26K | 58K | 193K |
| Total Assets | 466K | 481K | 463K | 446K | 469K |
| Total Liabilities | 124K | 45K | 42K | 93K | 45K |
| Shareholder Equity | 342K | 436K | 421K | 353K | 424K |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | 5K | -20K | -26K | -58K | -193K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
881K
+1.0% YoY
Capital Expenditures
70K
+22.9% YoY
Free Cash Flow
951K
+3.0% YoY
Key ratios
Gross Margin
-28.4%
Operating Margin
-746.7%
Net Margin
-772.8%
ROE
-116.3%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.